Replies to post #1766 on Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Mystery solved regarding CASI's SP rise. CEO buying! To the tune of $419,178. First, let me put in a plug for iHUB before I continue. I found the info below by clicking on the SEC links right on iHUBs CASI page above where we post. Pretty convenient.

Common Stock 9/14/2017 P 187625 A $1.22 (1) 212323 D
Common Stock 9/15/2017 P 127702 A $1.49 (1) 340025 D
Common Stock 9/18/2017 P 173500 A $1.75 (1) 513525 D
Common Stock 9/19/2017 P 34002 A $1.78 (1) 547527 D

He started buying after the PR was released i.e. the PR info became common knowledge releasing him of any insider trading accusations so what's in the PR that hints on why he's buying. Is it for CASI's import drug registration clinical trial application for EVOMELA being granted Priority Review? or is it for one or both of the following

• Triple Negative Breast Cancer (TNBC). The accrual to the investigator sponsored Phase 2 study in patients with previously treated advanced and metastatic TNBC is complete and the correlative biomarker/genomics analysis is ongoing. The data will be presented at the 2017 San Antonio Breast Cancer Symposium.
• Fibrolamellar Carcinoma (FLC). The accrual to this ongoing Phase 2 study is complete and is in the follow up phase. It is anticipated that the data from this study will be submitted to a medical conference for presentation in 2018.
Dr. Alex Zukiwski, M.D, CASI's Chief Medical Officer, commented, "ENMD-2076 has been investigated in a number of tumor types based on the known mechanism of action and the oncogenic pathways of the specific malignancy. Although anticancer activity was observed in the clear cell ovarian carcinoma and soft tissue sarcoma studies, the level of single agent activity does not support the development of ENMD-2076 in these two tumor types as a monotherapy. We look forward to providing an update on the ENMD-2076 Triple Negative Breast Cancer and Fibrolamellar Carcinoma data in the next few months."

Me thinks I'll be paying attention to the the 2017 San Antonio Breast Cancer Symposium a little more closely then I thought I would be.